Knee cartilage barely renews over a human lifetime, explaining why five new osteoarthritis drugs struggle to relieve pain

Knee cartilage barely renews over a human lifetime, explaining why five new osteoarthritis drugs struggle to relieve pain

The age of collagen in cartilage has been measured using the radioactive trace of twentieth-century nuclear tests: it "freezes" at the moment a person stops growing and remains unchanged from that point on. Osteoarthritis affects 595 million people worldwide. On September 28, the author of the longevity account agingroy compiled a map on X of five experimental drugs attempting to work around this property of the joint.

In 2016, Danish researchers took cartilage samples from 23 people and measured the fraction of radioactive carbon-14 in the collagen. Nuclear tests of the 1950s and 1960s raised the atmospheric concentration of carbon-14; after the test ban in 1963 it has been gradually declining, and a cell incorporates atmospheric carbon into a molecule at the moment of synthesis, so the C-14 level in the molecule becomes a fixed timestamp of the year it was built. In knee cartilage collagen, that timestamp barely shifts: the tissue forms during skeletal growth and remains the same molecule for the rest of life, equally in 15 people with osteoarthritis and in 8 with healthy cartilage.

The collagen matrix of human joint cartilage is a virtually permanent structure: in adults it undergoes no meaningful renewal, even as the disease progresses.

The reason lies in the architecture of the tissue itself: cartilage has no blood vessels, and its sparse chondrocytes are nourished only by diffusion from the synovial fluid.

This is an extreme case even among tissues traditionally considered non-renewing. Cardiac muscle was long regarded as the model of zero cell replacement, but the same radiocarbon method showed that it does renew, just slowly: about 1% of cardiomyocytes per year at age 25, declining to 0.45% by age 75. In cartilage, that figure is indistinguishable from zero.

For decades the only options were painkillers, steroid injections, or joint replacement. Since cartilage does not repair itself, the remaining strategies are either to relieve the external load on it (mechanical, inflammatory, neural) or to deliver what its cells cannot produce on their own.

Semaglutide, a weight-loss injection (Ozempic, Wegovy), in 407 people with obesity and knee osteoarthritis reduced pain by 42 points out of a hundred versus 28 for placebo over 68 weeks, with weight falling by 14%. Lorecivivint, an intra-articular injection that blocks the Wnt pathway driving cartilage destruction: its Phase 3 trial did not surpass placebo on pain; the figure of "5 points out of a hundred below placebo at one year" was reported by the developer Biosplice itself from the two-year extension of that trial. LEVI-04, an intravenous infusion targeting neurotrophin-3, a protein that sensitizes pain-sensing nerves in the joint, in 518 people over four months relieved pain by 0.8 points out of ten more than placebo. PCRX-201, a single-dose gene therapy that inserts into the joint the gene for the anti-inflammatory protein IL-1Ra, which activates only during inflammation, in 72 people maintained its effect for three years without a placebo group. Sprifermin, the only one of the five that directly grows cartilage through fibroblast growth factor FGF-18, in 549 people grew cartilage by 0.05 mm more than placebo over two years, and the gain persisted at five years.

Only sprifermin demonstrably grew cartilage, yet its pain relief was indistinguishable from placebo. Among placebo-controlled trials, the strongest pain reduction came from weight loss.

Cartilage volume and pain in osteoarthritis move independently: a drug that repairs the joint's structure can still leave the source of suffering untouched.

In aged mice, researchers have already tried to close a similar gap from the other direction. In a Stanford experiment, blocking the enzyme 15-PGDH directly in the joint restored signs of healthy hyaline tissue in the cartilage, and in a separate knee-injury model the same injections reduced cartilage destruction while also improving the animals' gait and reducing signs of pain, so that structure and pain shifted in the same direction. Human cartilage trials for this enzyme have yet to begin: the gap between joint structure and pain on agingroy's map marks the current limit of drugs already tested in people, not an inherent law of the disease.